However, although del(5q) is a key pathogenic event in 5q− syndrome, some co-occurring somatic mutations, including TP53, SF3B1, CSNK1A1 and RUNX1 mutations, affect the outcomes of these patients, reducing the response to treatment and/or increasing the risk of AML development. The gene discussed is RUNX1; the disease is acute myeloid leukemia.